Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of biomarkers in Saizen-treated prepubertal children with growth hormone deficiency or Turner syndrome
2004-005054-31Phase 4Completed
- Sponsor
- Merck Serono
- Start
- May 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin in growth hormone deficiency (GHD) and Turner syndrome (TS) (2 arms), sponsored by Merck Serono. Primary endpoint: Most responsive serum biomarkers after one month of Saizen therapy. Started May 2005; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)Turner syndrome (TS)
Beyond the preview
Go deeper on 2004-005054-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005054-31.